WO2010059242A2 - Compositions diagnostiques de maladie neurodégénérative et procédés d'utilisation - Google Patents

Compositions diagnostiques de maladie neurodégénérative et procédés d'utilisation Download PDF

Info

Publication number
WO2010059242A2
WO2010059242A2 PCT/US2009/006238 US2009006238W WO2010059242A2 WO 2010059242 A2 WO2010059242 A2 WO 2010059242A2 US 2009006238 W US2009006238 W US 2009006238W WO 2010059242 A2 WO2010059242 A2 WO 2010059242A2
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
subject
polynucleotide
astrocytic
level
Prior art date
Application number
PCT/US2009/006238
Other languages
English (en)
Other versions
WO2010059242A3 (fr
Inventor
Rita G. Sattler
Jeffrey D. Rothstein
Richard Chipkin
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Priority to US13/130,744 priority Critical patent/US20120094295A1/en
Publication of WO2010059242A2 publication Critical patent/WO2010059242A2/fr
Publication of WO2010059242A3 publication Critical patent/WO2010059242A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Abstract

La présente invention concerne généralement des diagnostics qui utilisent des biomarqueurs altérés dans une maladie neurodégénérative, ainsi que des procédés pour l’utilisation de tels marqueurs dans la surveillance de la progression d’une maladie et l’identification d’agents utiles pour le traitement d’une maladie neurodégénérative.
PCT/US2009/006238 2008-11-21 2009-11-20 Compositions diagnostiques de maladie neurodégénérative et procédés d'utilisation WO2010059242A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/130,744 US20120094295A1 (en) 2008-11-21 2009-11-20 Neurodegenerative disease diagnostic compositions and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11683608P 2008-11-21 2008-11-21
US61/116,836 2008-11-21
US18110809P 2009-05-26 2009-05-26
US61/181,108 2009-05-26

Publications (2)

Publication Number Publication Date
WO2010059242A2 true WO2010059242A2 (fr) 2010-05-27
WO2010059242A3 WO2010059242A3 (fr) 2010-09-23

Family

ID=42198724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/006238 WO2010059242A2 (fr) 2008-11-21 2009-11-20 Compositions diagnostiques de maladie neurodégénérative et procédés d'utilisation

Country Status (2)

Country Link
US (1) US20120094295A1 (fr)
WO (1) WO2010059242A2 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012725A2 (fr) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Méthodes de dépistage de maladies ou d'affections à l'aide de cellules phagocytaires
WO2013188828A1 (fr) 2012-06-15 2013-12-19 Harry Stylli Méthodes de détection de maladies ou d'états au moyen de cellules infectées en circulation
WO2013188846A1 (fr) 2012-06-15 2013-12-19 Harry Stylli Procédés de détection de maladies ou d'états
WO2017042196A3 (fr) * 2015-09-08 2017-04-20 Ecole Polytechnique Federale De Lausanne (Epfl) Agents et procédés d'utilisation de ceux-ci pour la prévention et le traitement de la sénescence de cellules souches
US9772335B2 (en) 2011-02-24 2017-09-26 The Trustees Of The University Of Pennsylvania Biomarkers for seizures
US9810698B2 (en) 2004-04-15 2017-11-07 University Of Florida Research Foundation, Incorporated Neural proteins as biomarkers for nervous system injury and other neural disorders
US10041959B2 (en) 2009-09-14 2018-08-07 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
US10934589B2 (en) 2008-01-18 2021-03-02 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
US10961578B2 (en) 2010-07-23 2021-03-30 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US11111537B2 (en) 2010-07-23 2021-09-07 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP4303584A2 (fr) 2010-07-23 2024-01-10 President and Fellows of Harvard College Procédés de détection de signatures de maladies ou pathologies dans des liquides biologiques

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101734645B1 (ko) * 2015-05-18 2017-05-11 (주)에이엔티랩스 초기 알츠하이머 병 또는 경도 인지 장애 진단 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060457B2 (en) * 1998-03-18 2006-06-13 Johns Hopkins University Aberrant glutamate transporters and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADELE J. VINCENT, ET AL.: 'Genetic expression profile of olfactory ensheathing cells is distinct from that of Schwann cells and astrocytes' GLIA vol. 51, no. 2, 2005, pages 132 - 147 *
CLAUDIA PITZER, ET AL.: 'Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis' BRAIN vol. 131, 03 October 2008, pages 3335 - 3347 *
MARY L. MICHAELIS: 'Drugs Targeting Alzheimer's Disease: Some Things Old and Some Things New' THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS vol. 304, no. 3, 2003, pages 897 - 904 *
SUMIO OHTSUKI AND TETSUYS TERASAKI: 'Contribution of Carrier-Mediated Transport Systems to the Blood-Brain Barrier as a Supprting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development' PHARMACEUTICAL RESEARCH vol. 24, no. 9, 2007, pages 1745 - 1758 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11221342B2 (en) 2004-04-15 2022-01-11 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US9810698B2 (en) 2004-04-15 2017-11-07 University Of Florida Research Foundation, Incorporated Neural proteins as biomarkers for nervous system injury and other neural disorders
US10330689B2 (en) 2004-04-15 2019-06-25 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US10934589B2 (en) 2008-01-18 2021-03-02 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
US11001894B2 (en) 2008-01-18 2021-05-11 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
US10934588B2 (en) 2008-01-18 2021-03-02 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
US10041959B2 (en) 2009-09-14 2018-08-07 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
EP4303584A2 (fr) 2010-07-23 2024-01-10 President and Fellows of Harvard College Procédés de détection de signatures de maladies ou pathologies dans des liquides biologiques
US11111537B2 (en) 2010-07-23 2021-09-07 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
WO2012012725A2 (fr) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Méthodes de dépistage de maladies ou d'affections à l'aide de cellules phagocytaires
US10961578B2 (en) 2010-07-23 2021-03-30 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US11035866B2 (en) 2011-02-24 2021-06-15 The Trustees Of The University Of Pennsylvania Biomarkers for seizures
US9983219B2 (en) 2011-02-24 2018-05-29 The Trustees Of The University Of Pennsylvania Biomarkers for seizures
US9772335B2 (en) 2011-02-24 2017-09-26 The Trustees Of The University Of Pennsylvania Biomarkers for seizures
WO2013188846A1 (fr) 2012-06-15 2013-12-19 Harry Stylli Procédés de détection de maladies ou d'états
WO2013188828A1 (fr) 2012-06-15 2013-12-19 Harry Stylli Méthodes de détection de maladies ou d'états au moyen de cellules infectées en circulation
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
WO2017042196A3 (fr) * 2015-09-08 2017-04-20 Ecole Polytechnique Federale De Lausanne (Epfl) Agents et procédés d'utilisation de ceux-ci pour la prévention et le traitement de la sénescence de cellules souches

Also Published As

Publication number Publication date
US20120094295A1 (en) 2012-04-19
WO2010059242A3 (fr) 2010-09-23

Similar Documents

Publication Publication Date Title
US20120094295A1 (en) Neurodegenerative disease diagnostic compositions and methods of use
US20180106817A1 (en) Protein biomarkers and therapeutic targets for renal disorders
Khalil Biomarker discovery: a proteomic approach for brain cancer profiling
EP2971285B1 (fr) Biomarqueurs sanguins prédisant la persistance d'un dysfonctionnement cognitif après commotion
JP6581247B2 (ja) 前立腺癌の診断および処置におけるマーカーの使用
EP2569446B1 (fr) Marqueurs de diagnostique pour les maladies neuropsychiatriques
US20070292869A1 (en) Compositions and Methods for Analyzing Renal Cancer
JP6198752B2 (ja) 胃癌のバイオマーカー及びその使用
JP6786499B2 (ja) 膵癌のバイオマーカー
JP2011521630A (ja) ゲノミクスまたはプロテオミクス発現プロファイリングを用いて腎同種移植の拒絶反応を診断する方法
KR20160045547A (ko) 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법
US20180140585A1 (en) Biomolecules involved in alzheimer's disease
US11955241B2 (en) Pathogenic biomarkers and serum extracellular vesicular biomarkers associated with vascular malformation of endothelial cells, and uses thereof
KR101992060B1 (ko) 알츠하이머치매 진단 체액 바이오마커 후보 단백4종
WO2019099706A1 (fr) Marqueurs pour le diagnostic et le traitement de la stéatohépatite non alcoolique (nash) et de la fibrose hépatique avancée
US20160327572A1 (en) Biomarkers for Dementia and Dementia Related Neurological Disorders
WO2013090857A1 (fr) Identification de deux nouveaux marqueurs biologiques pour la maladie de niemann-pick de type c
CN112567246A (zh) 治疗脊髓性肌萎缩症的方法
Jericó et al. Profiling TREM2 expression in amyotrophic lateral sclerosis
Kovacevic et al. Urine proteomic analysis in cystinuric children with renal stones
CN113774140A (zh) 一种预测结直肠癌对奥沙利铂治疗敏感性的产品
JP5568807B2 (ja) プロテオミクス解析を用いたメラノーママーカーの同定
CN113817829A (zh) 生物标志物在制备预测结直肠癌对奥沙利铂治疗敏感性的产品中的用途
CN115058512A (zh) 铁死亡相关基因在鉴定缺血性脑卒中的应用
EP2607494A1 (fr) Biomarqueurs pour l'évaluation du risque de cancer des poumons

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09827891

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13130744

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09827891

Country of ref document: EP

Kind code of ref document: A2